Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
1.530
+0.050 (3.38%)
Aug 28, 2025, 4:00 PM - Market closed

Trinity Biotech Statistics

Total Valuation

Trinity Biotech has a market cap or net worth of $5.74 million. The enterprise value is $101.09 million.

Market Cap5.74M
Enterprise Value 101.09M

Important Dates

The next estimated earnings date is Tuesday, September 9, 2025, before market open.

Earnings Date Sep 9, 2025
Ex-Dividend Date n/a

Share Statistics

Trinity Biotech has 3.71 million shares outstanding. The number of shares has increased by 134.62% in one year.

Current Share Class n/a
Shares Outstanding 3.71M
Shares Change (YoY) +134.62%
Shares Change (QoQ) +27.65%
Owned by Insiders (%) 15.24%
Owned by Institutions (%) 20.12%
Float 16.19M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.09
Forward PS 0.08
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.64
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.28

Current Ratio 1.28
Quick Ratio 0.62
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1.15

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -10.53%
Return on Invested Capital (ROIC) -15.71%
Return on Capital Employed (ROCE) -19.25%
Revenue Per Employee $153,504
Profits Per Employee -$79,274
Employee Count401
Asset Turnover 0.76
Inventory Turnover 2.04

Taxes

In the past 12 months, Trinity Biotech has paid $486,000 in taxes.

Income Tax 486,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -38.80% in the last 52 weeks. The beta is 0.77, so Trinity Biotech's price volatility has been lower than the market average.

Beta (5Y) 0.77
52-Week Price Change -38.80%
50-Day Moving Average 0.93
200-Day Moving Average 0.85
Relative Strength Index (RSI) 60.12
Average Volume (20 Days) 13,521,182

Short Selling Information

Short Interest 1.99M
Short Previous Month 368,755
Short % of Shares Out 3.88%
Short % of Float n/a
Short Ratio (days to cover) 0.21

Income Statement

In the last 12 months, Trinity Biotech had revenue of $61.56 million and -$31.79 million in losses. Loss per share was -$9.16.

Revenue61.56M
Gross Profit 21.44M
Operating Income -13.70M
Pretax Income -21.51M
Net Income -31.79M
EBITDA -13.03M
EBIT -13.70M
Loss Per Share -$9.16
Full Income Statement

Balance Sheet

The company has $5.17 million in cash and $100.76 million in debt, giving a net cash position of -$95.60 million or -$25.74 per share.

Cash & Cash Equivalents 5.17M
Total Debt 100.76M
Net Cash -95.60M
Net Cash Per Share -$25.74
Equity (Book Value) -35.18M
Book Value Per Share -9.79
Working Capital 9.03M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$4.19 million and capital expenditures -$405,000, giving a free cash flow of -$4.60 million.

Operating Cash Flow -4.19M
Capital Expenditures -405,000
Free Cash Flow -4.60M
FCF Per Share -$1.24
Full Cash Flow Statement

Margins

Gross margin is 34.83%, with operating and profit margins of -22.26% and -51.64%.

Gross Margin 34.83%
Operating Margin -22.26%
Pretax Margin -49.92%
Profit Margin -51.64%
EBITDA Margin -21.17%
EBIT Margin -22.26%
FCF Margin n/a

Dividends & Yields

Trinity Biotech does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -134.62%
Shareholder Yield -134.62%
Earnings Yield -578.44%
FCF Yield -83.63%
Dividend Details

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on February 23, 2024. It was a reverse split with a ratio of 1:5.

Last Split Date Feb 23, 2024
Split Type Reverse
Split Ratio 1:5

Scores

Trinity Biotech has an Altman Z-Score of -0.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.73
Piotroski F-Score 3